Lincoln Pharma Q3 FY26 Net Profit Surges 37.7% to ₹28.60 Cr; Revenue up 13.49%
Lincoln Pharmaceuticals reported a Q3 FY26 consolidated net profit of ₹28.60 crore, up 37.70% YoY. Revenue rose 13.49% to ₹166.32 crore. For 9MFY26, net profit was ₹76.26 crore (up 7.76%) and revenue was ₹483.75 crore (up 6.31%). The company targets ₹1,000 crore revenue in 3 years with 15-18% annual growth.
The significant increase in profit and revenue, coupled with ambitious growth targets and positive management commentary, indicates a substantial positive impact on investor sentiment and the company's financial outlook.
The company reported strong year-on-year growth in net profit and revenue for both the quarter and nine-month period, along with positive future growth targets and reaffirmation of credit ratings.
Lincoln Pharmaceuticals Limited announced its financial results for the quarter and nine months ended December 31, 2025. The company reported a consolidated net profit of ₹28.60 crore for Q3 FY26, marking a significant year-on-year increase of 37.70% from ₹20.77 crore in Q3 FY25. Revenue from operations for the quarter stood at ₹166.32 crore, a 13.49% rise from ₹146.55 crore in the same period last year. EBITDA for Q3 FY26 was reported at ₹38.74 crore, an 18.73% increase year-on-year.
For the nine-month period ended December 2025 (9MFY26), the consolidated net profit was ₹76.26 crore, up 7.76% from ₹70.77 crore in 9MFY25. Revenue from operations for 9MFY26 reached ₹483.75 crore, a 6.31% growth compared to ₹455.05 crore in 9MFY25. EBITDA for 9MFY26 was ₹110.48 crore, a 6.10% increase year-on-year.
The company has set a target to achieve a revenue of ₹1,000 crore within the next three years, aiming for a 15-18% annual growth rate. This growth will be driven by expansion into high-value product lines, entry into new markets, and strong performance in cardiac, diabetic, dermatology, and ENT segments. Lincoln Pharmaceuticals is also focused on expanding its global footprint from over 60 countries to 90 countries in the next 2-3 years, with recent approvals from TGA-Australia and EU GMP.
Mr. Mahendra Patel, Managing Director, expressed confidence in sustaining the growth trajectory, supported by a strong R&D pipeline with over 100 new development programs and a debt-free balance sheet. Foreign Institutional Investors' holding in the company as of December 31, 2025, was 4.70%. CRISIL Ratings reaffirmed its 'CRISIL A/Stable/CRISIL AI' ratings on the company's bank facilities on January 9, 2026.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.